Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Global Phase III clinical trial of zabadinostat in combination with an immune checkpoint inhibitor for micro-satellite stable colorectal cancer

Next Previous
Trial Profile

Global Phase III clinical trial of zabadinostat in combination with an immune checkpoint inhibitor for micro-satellite stable colorectal cancer

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zabinostat (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 05 Jan 2023 According to a Celleron Therapeutics media release, Celleron Therapeutics has merged with the Argonaut Therapeutics to form IngenOx Therapeutics (www.ingenox.com).
  • 08 Jul 2022 New trial record
  • 29 Jun 2022 According to a Celleron Therapeutics media release, the company expect to initiate this trial in 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top